MENU
+Compare
PCSA
Stock ticker: NASDAQ
AS OF
Jan 22, 04:58 PM (EDT)
Price
$0.70
Change
-$0.03 (-4.11%)
Capitalization
2.6M

PCSA Processa Pharmaceuticals Forecast, Technical & Fundamental Analysis

Industry Biotechnology
PCSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PCSA with price predictions
Jan 08, 2025

PCSA in -11.20% downward trend, sliding for three consecutive days on December 23, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PCSA declined for three days, in of 297 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where PCSA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 07, 2025. You may want to consider a long position or call options on PCSA as a result. In of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PCSA just turned positive on January 06, 2025. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in of 191 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.698) is normal, around the industry mean (15.017). P/E Ratio (0.000) is within average values for comparable stocks, (88.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.838). PCSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (265.166).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PCSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PCSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PCSA is expected to report earnings to rise 25.00% to -10 cents per share on March 28

Processa Pharmaceuticals PCSA Stock Earnings Reports
Q4'23
Est.
$-0.10
Q3'23
Beat
by $0.02
Q2'23
Beat
by $0.05
Q1'23
Beat
by $0.05
Q4'22
Missed
by $0.49
The last earnings report on November 08 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 51.60K shares outstanding, the current market capitalization sits at 2.60M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7380 Coca Cola Drive
Phone
+1 443 776-3133
Employees
13
Web
https://www.processapharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COHR103.204.91
+5.00%
Coherent Corp
GECC10.870.18
+1.68%
Great Elm Capital Corp
WGO48.420.67
+1.40%
Winnebago Industries
MPLN15.70-0.37
-2.30%
MultiPlan Corporation
NUWE1.17-0.04
-3.31%
Nuwellis Inc

PCSA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PCSA has been loosely correlated with INO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PCSA jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCSA
1D Price
Change %
PCSA100%
-10.02%
INO - PCSA
38%
Loosely correlated
+5.77%
ONCO - PCSA
33%
Loosely correlated
+1.89%
EDIT - PCSA
28%
Poorly correlated
-0.82%
ONC - PCSA
27%
Poorly correlated
+4.10%
VKTX - PCSA
27%
Poorly correlated
+0.67%
More